Introduction
Wound healing is a complex process which encompasses three phases: inflammation, granulation tissue formation and tissue remodeling. 1 These events are triggered by cytokines and growth factors which are released at the site of injury. Angiogenesis, the sprouting of new blood vessels from a pre-existing network, 2 is necessary to allow migration of leukocytes and growth factors and oxygen supply during granulation tissue formation. Once granulation tissue completely replaces the initial fibrin clot, tissue remodeling begins and the new vessels start to regress.
Vascular endothelial growth factor is one of the most important endothelial growth factors and it is a dimeric glycoprotein characterized by the six isoforms VEGF 121 , VEGF 145 , VEGF 165 , VEGF 183 , VEGF 189 , VEGF 206 , derived from alternative splicing. 3 It has mitogenic activity on endothelial cells in vitro, shows angiogenic properties in vivo 4, 5 and enhances vascular permeability of blood vessels.
VEGF plays an important role in the induction of angiogenesis during wound healing and its expression is upregulated by hypoxia both in vivo and in vitro. 6 In adult skin, VEGF expression is almost undetectable under phy- siologic conditions, while its up-regulation occurs in hyperplastic epidermis of healing wounds 7 and psoriatic skin. 8 VEGF is a potent mitogen for dermal microvascular endothelial cells, 9 it is expressed in keratinocytes of healing wounds 10, 11 and acts in a paracrine manner on dermal microvessels, leading to increased skin vascularity. 12, 13 Recently, the in vivo activity of hVEGF promoter has been shown in wounded transgenic mouse skin. 14 Elevated VEGF mRNA levels are found in normal mice during granulation tissue formation, while levels are significantly reduced in db/db diabetic mice. 11 A similar reduction of VEGF gene expression has been reported in non-obese diabetic mice in response to hindlimb ischemia. Since genetically and streptozotocin-induced diabetic mice show impaired wound healing when compared with healthy animals, [15] [16] [17] it is possible that this may reflect, at least in part, an inadequate VEGF expression.
Therefore, to address the importance of VEGF in vivo in skin angiogenesis during wound repair in diabetes and to identify a potential therapeutic tool, we investigated the effect of gene therapy with an adenoviral vector carrying the VEGF 165 gene on excisional wound healing in streptozotocin-induced diabetic mice.
Our results show that adenovirus-mediated VEGF 165 gene transfer induces accelerated wound healing by promoting angiogenesis at the site of injury and suggest that topical VEGF 165 gene transfer should be evaluated for clinical application for the treatment of chronic nonhealing wounds in diabetic patients.
Results

AdCMV.VEGF 165 transduction in skin wounds
Replication-deficient recombinant adenovirus vectors can transfer genes to several cell types both in vitro and in vivo. [18] [19] [20] Furthermore, they can transfer genes directly to skin cells in vivo. 21 We first assessed whether an adenovirus vector carrying the VEGF 165 cDNA could efficiently transduce mouse skin after its topical application. Western blot analysis was performed on cell lysates from wounds treated either with the control vector AdCMV.LacZ or AdCMV.VEGF 165 ; exposure to the adenovirus vector occurred either 48 or 72 h before the death of the animals. As shown in Figure 1 , VEGF 165 was abundantly expressed in transduced skin while trace amounts, corresponding to endogenous VEGF, ie murine VEGF 164 , were present in AdCMV.LacZ-treated control samples.
VEGF 165 enhances wound healing in diabetic mice
Analysis of wound closure of AdCMV.VEGF 165 -, AdCMV.LACZ-, saline-treated and nondiabetic CD1 mice was performed through digital processing of pictures taken at the time of wounding (time 0) and at day 2, 3, 5, 7, 9, 11 and 13 days after skin damage, ie until wound closure was complete in all groups. A representative example of wound closure of treated and control animals is shown in Figure 2a . Average results (Figure 2b) show that treatment of mice with AdCMV.VEGF 165 accelerated wound healing when compared with treatment with control vector or to the uninfected control (saline). Interestingly, diabetic AdCMV.VEGF 165 -treated mice healed similarly to nondiabetic CD1 mice (Figure 2b) . A statistically significant difference between AdCMV.VEGF 165 -treated mice and both AdCMV.LACZand saline-treated mice was already apparent at day 3 after treatment and persisted at all time-points evaluated from day 3 to day 9. It is noteworthy that at day 3 wound healing was accelerated in AdCMV.VEGF 165 -treated mice also versus nondiabetic CD1 mice. However, at later timepoints this difference disappeared. 
Effect of
VEGF 165 promotes angiogenesis in wounds
In order to investigate whether the ability of AdCMV.VEGF 165 to accelerate wound closure was associated with an angiogenic effect at the site of injury, PECAM-1 staining was performed on central sections 7 days after wounding. This staining allowed estimation of the density of PECAM-1-positive vessels in
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AdCMV.VEGF 165 treated mice (Figure 4c ) versus control mice (Figure 4a and b) . A two-and a 3.7-fold increase in blood vessel density was observed in AdCMV.VEGF 165 -versus AdCMC.LacZ-and saline-treated mice, respectively (Figure 4d) . In order to further analyze the angiogenic response to VEGF treatment, the arteriolar density was measured by means of ␣-smooth muscle actin immunostaining and by morphometric analysis. Such analysis revealed that 7 days after skin wounding and topical application of adenoviral vectors or saline, a significant increase occurred in the length density of arterioles with a luminal diameter of 4 to 41 m in AdCMV.VEGF 165 -versus AdCMC.LacZ-and salinetreated mice (two-fold and 3.1-fold, respectively) ( Figure  5 ). The angiogenic effect of VEGF may be underestimated by the increase in vascular permeability induced by the growth factor.
Discussion
The results of the present study show that adenovirusmediated VEGF 165 gene transfer to excisional wounds in diabetic mice enhances healing and is associated with a significant angiogenic response.
Skin ulcers, mostly affecting the foot, are a common complication of diabetes mellitus 22 and they can be due to different causes which frequently coexist. Atherosclerosis of large and medium-sized arteries and microangiopathy affecting small vessels cause ischemic ulcers. 23 Nevertheless, other patients develop neurotrophic ulcerations in the absence of ischemia. Both ischemic and neurotrophic ulcerations can be complicated by localized infection and heal with considerable difficulty.
Altered wound repair is present in animal models of diabetes such as non-obese diabetic mice (NOD), db/db mice [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and mice in which the diabetes was induced by treatment with streptozotocin. NOD mice develop a form of diabetes similar to human type-I insulin-dependent diabetes, also known as type 1 diabetes, that is an organspecific autoimmune disease resulting from the destruction of insulin-producing pancreatic ␤ cells. 24 In NOD mice impairment of angiogenesis and a significant reduction of VEGF expression compared with VEGF levels in normal C57 mice have been documented. Specifically, the impairment of angiogenesis was characterized by decreased capillary density and significant blood flow reduction in ischemic hindlimbs. 25 Diabetes in the C57 BL7KSJ db mouse (db/db mouse) is similar to maturity-onset diabetes (non-insulin-dependent diabetes mellitus, NIDDM) in humans and is characterized by obesity, infertility, hyperphagia and marked hyperglycemia. 26 Db/db mice show a significant reduction of VEGF mRNA expression during the healing process.
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Treatment of mice with streptozotocin induces an insulin-deficient diabetes that is similar to type I diabetes and several strains of mice including CD1 have been rendered diabetic by this method. 27, 43 VEGF may have both direct and indirect effects on wound healing by increasing endothelial cell proliferation and vascular permeability, thus allowing the delivery of plasma proteins and influx of migrating cells to the site of injury. 28 Further, in vitro studies have shown that a high glucose concentration leads to decreased endothelial cell prolifer-
Figure 4 Determination of skin vessel density by immunohistochemical analysis. Total vessel density was determined 7 days after wounding by anti-PECAM-1 staining (×200 magnification). Representative staining of (a) saline-treated, (b) AdCMV.LacZ-treated and (c) AdCMV.VEGF 165 -treated wounds. (d) Total vessel density was significantly increased in VEGF 165 -treated as compared with saline-and AdCMV.LacZ-treated wounds (P Ͻ 0.05).
Figure 5 Evaluation of arteriolar density in treated mice. Arterioles length density in wounded skin measured by ␣-smooth muscle actin staining showed a significant increase of arterioles length density in mice treated with AdCMV.VEGF 165 as compared with saline-and Ad.CMV.LacZ-treated mice (P Ͻ 0.05).
ation and differentiation, as well as cell cycle and morphological alterations of endothelial cells. 29, 30 The expression of VEGF and VEGF receptors is upregulated, during the normal wound healing process, in migrating keratinocytes, 31, 32 in sprouting blood vessels at the wound edge and in the granulation tissue. VEGF production is stimulated during this process, besides by hypoxia, by key molecules such as epidermal growth factor (EGF) family members, keratinocyte growth factor (KGF) and transforming growth factor-␤1 (TGF-␤1) 11 accumulating at the wound site.
In order to enhance wound repair, supplementation of recombinant angiogenic growth factors, such as nerve growth factor (NGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) 2 and granulocyte-macrophage stimulating factor (GM-CSF) has been used both in animal models 15, 33 and in clinical trials of patients with chronic ulcers. 34, 35 Treatment with recombinant growth factors has often been successful in increasing re-epithelialization, granulation tissue formation and extracellular matrix deposition, thus enhancing wound healing. On the other hand, short half-life of these growth factors, mostly due to the activity of tissue proteases, and their elevated costs, have limited their use in clinical trials. ' Therapeutic angiogenesis ' with angiogenic factors inserted into plasmids or adenoviral vectors has been widely utilized in both animal models and in clinical trials to ameliorate peripheral, 25 cardiac ischemia 36, 37 and wound repair. [38] [39] [40] VEGF gene transfer has been shown to enhance angiogenesis in animal models of hindlimb and cardiac ischemia and under these experimental conditions, it improves blood flow to the ischemic tissues. 25, 36, 41 In the present study VEGF 165 gene transfer, in the absence of experimentally induced ischemia, significantly improved wound healing in diabetic animals. Topical application into excisional wounds resulted in efficient VEGF 165 expression in mouse skin, where it induced an accelerated rate of closure by promoting angiogenesis at the site of injury. Treatment with AdCMV.VEGF 165 induced a rate of wound closure in diabetic mice similar to the one observed in CD1 nondiabetic mice thus indicating the efficacy of such treatment. On the other hand, a slower and comparable closure rate was shown in both AdCMV.LacZ-and saline-treated diabetic mice, suggesting that the accelerated healing of VEGF-treated animals was not secondary to the inflammatory response elicited by treatment with the adenoviral vectors.
In this study we show that VEGF 165 treatment induces healing by promoting neoangiogenesis at the site of injury. VEGF overexpression may have exerted a direct mitogenic effect on endothelial cells and also increased vascular permeability and macrophage infiltration. 42 In conclusion, adenovirus-mediated gene transfer of excisional wounds with VEGF 165 may be regarded as a therapeutic tool for the treatment of diabetic ulcers. Additional studies will be required to determine the clinical applicability of VEGF 165 gene transfer to improve wound healing in diabetic patients.
Materials and methods
Adenoviral vectors
The replication-deficient adenovirus vector containing the cDNA for human VEGF 165 (AdCMV.VEGF 165 ) has been previously described. 43 AdCMV.LacZ carries the cDNA for the E. coli LacZ gene and was used as a control vector.
Animal wound model CD1 male mice were obtained from Charles River (Calco, Italy). These mice were rendered diabetic by intraperitoneal injection of streptozotocin (Sigma-Aldrich, St Louis, MO, USA) at 1.2 mg/30 g weight/day for 5 consecutive days. 44 After 7 days, glycemia was measured and animals with glycemia of 200 to 400 mg/dl were selected for further studies. Mice were anesthetized with i.m. injection of 2.5% avertin (100% Avertin: 10 g of 2,2,2-tribromoethyl alcohol (Sigma) and 10 ml of tert-amyl alcohol, (Sigma)). The dorsum was clipped free of hair and a full-thickness wound of 3.5 mm diameter was created using a biopsy punch.
Adenovirus-mediated gene transfer (AdCMV.VEGF 165 or AdCMV.LacZ) was performed by placing 10 8 p.f.u. in 10 l of PBS directly on the wound. Another group of diabetic mice was treated by placing 10 l of PBS on the wound.
Adenovirus transduction efficiency in wounded mouse skin Animals were killed 48 h and 72 h after treatment, and wounded areas were surgically removed. Skin samples were trimmed with small scissors on ice and 3 ml of RIPA buffer (1 × PBS, 1% NP40, 150 mM NaCl, 0.1% SDS) containing proteinase inhibitors (PMSF, aprotinin and sodium orthovanadate) were added to each gram of tissue sample. Tissues were then homogenized on ice using a blender (PBI International, Milano, Italy), incubated for 30 min on ice and centrifuged at 14 000 r.p.m.
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For Western blot analysis, 60 g of each sample were run on a 12% polyacrylamide gel. The gel was then transferred on to nitrocellulose membrane (S&S, Amersham Pharmacia Biotech, UK) following standard procedures, and VEGF 165 expression was detected using a specific polyclonal rabbit antibody (1:100 dilution) (R&D, Minneapolis, MN, USA) and a secondary HRP-anti-rabbit antibody (1:10 000 dilution) for ECL detection (Amersham) following standard procedures.
Determination of wound closure rate
To compare the rate of wound closure between AdCMV.VEGF 165 -treated, AdCMV.LacZ-treated and saline-treated diabetic mice, as well as CD1 non-diabetic mice, animals were photographed at day 0, 2, 3, 5, 7, 9, 11 and 13 after treatment. Pictures were digitally processed and areas of wounds were calculated using the KS300 system (Zeiss, Jena, Germany). For each sample the rate of the healing process was measured as a ratio of the area at each time-point divided by the area at time 0 (ie immediately after the wound). Seven to 29 animals/group were analyzed as a total of six independent experiments.
Histology
Wounds and surrounding skin areas were surgically removed, fixed in 10% buffered formalin for 48 h at room temperature and embedded in paraffin. Sections (4 m thickness) were mounted on glass slides treated with poly-L-lysine (Sigma) and subjected to hematoxylin-eosin (H-E) staining following standard techniques. Serial sections were prepared for each specimen and central sections of the wounds were identified by measuring the largest epithelial gap, ie the maximal distance between the epithelial edges. Sections were then subjected to immunohistochemical analysis and quantification of granulation tissue by two independent investigators.
H-E staining of the granulation tissue areas was performed on diabetic mice treated with AdCMV.VEGF 165, AdCMV.LacZ or saline and killed 5 days after wounding. The areas were calculated with the Zeiss image analyzer KS300, at ×50 magnification and were expressed in mm 2 .
Immunohistochemistry and morphometric analysis
Immunohistochemical staining of the central region of wounds of treated mice, n = 5 in each group, killed on day 7 after wounding, was performed. Briefly, sections (4 m thickness) were processed with xylene, passed sequentially through graded alcohol, PBS-washed and then incubated with anti-PECAM-1 antibody (1:200 dilution) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature (RT). A biotinylated rabbit anti-goat immunoglobulin was used as secondary antibody (1:50 dilution) (Vector Laboratories, Peterborough, UK) for 1 h at RT, followed by treatment with avidin biotin complex (1:100 dilution) (Vectors Laboratories) for 1 h at RT. The sections were rinsed for 15 min in PBS and color development was performed with 3,3 ' -diaminobenzidine for 5 min. Sections were finally counterstained with hematoxylin to identify nuclei. A rabbit serum (1:10 dilution) was used as a negative control.
Vessel density was measured as a number of PECAM-1-positive vessels (×400 magnification) divided by the total area (mm 2 ) of the central section by two independent investigators. The areas were calculated with the Zeiss image analyzer KS300.
Morphometric analysis was performed at day 7 after wounding. Five mice treated with either AdCMV.LacZ, AdCMV.VEGF 165 or saline were killed, skin samples were taken and fixed in formalin. The central sections were stained with anti-␣-smooth muscle actin antibody in order to identify intermediate-sized arteries and arterioles and to distinguish them from capillaries and veins. Briefly, sections were deparaffinized, rinsed with PBS, incubated at 37°C for 60 min with a monoclonal anti-␣-smooth muscle actin (clone 1A4, Sigma) (1:30 dilution), and subsequently incubated at 37°C for 1 h with antimouse IgG tetramethylrhodamine B isothiocyanate (TRITC)-labeled antibody diluted 1:60 in PBS. Finally, sections were rinsed in PBS and mounted in Vectashield (Vector Laboratories). For morphometric analysis, the skin total area was examined (×400 magnification) and the length of major and minor luminal diameters and wall thickness along the minor axis of each artery and arteriole were analyzed. 45 For ' n ' profiles counted in an area A, the length density (Ld) is equal to the sum of the ratio of the major or long axis to the minor or wide axis of each profile. Thus, Ld is equal to the length per unit volume in the same dimensional area: Ld = 1/A ΣR = ( R 1 + R 2 + R 3 + .. R n )/A. Arteriole length density was expressed per unit of volume (mm/mm 3 ) of skin. 45, 46 Statistical analysis All data are expressed as means ± s.e.m. Comparisons among different groups for continuous variables were carried out by analysis of Variance (ANOVA). Post-hoc pairwise comparisons were performed, when appropriate (ANOVA P Ͻ 0.05), using the Student-NewmanKeuls method. A P value of Ͻ0.05 was considered statistically significant.
